Current views of haemolytic streptococcal pathogenesis

Current Opinion in Infectious Diseases

Volumn 27, Issue 2, 2014, Pages 155-164

  Tan, Lionel K K ^a   Eccersley, Lydia R J ^b   Sriskandan, Shiranee ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

complement; fibrinolysis; Streptococcus dysgalactiae; Streptococcus pyogenes

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4 BINDING PROTEIN; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; FIBRINOGEN; IMMUNOGLOBULIN G; M PROTEIN; PLASMIN; PLASMINOGEN; POLYPEPTIDE ANTIBIOTIC AGENT; PROPERDIN; STREPTOKINASE; THROMBIN;

ANTIBACTERIAL ACTIVITY; ANTIGEN BINDING; ANTIMICROBIAL ACTIVITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BIOFILM; CHICKENPOX; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DIABETES MELLITUS; ENZYME ACTIVATION; FIBRINOLYSIS; GENE SEQUENCE; GROUP A STREPTOCOCCAL INFECTION; HONG KONG; IMMUNE EVASION; INFECTION RISK; INNATE IMMUNITY; INTRAVENOUS DRUG ABUSE; MOLECULAR PHYLOGENY; NONHUMAN; OBESITY; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; QUORUM SENSING; REVIEW; SCANNING ELECTRON MICROSCOPY; SCARLET FEVER; SOFT TISSUE INFECTION; STAPHYLOCOCCAL SKIN INFECTION; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS DYSGALACTIAE EQUISIMILIS; STREPTOCOCCUS GROUP C; STREPTOCOCCUS GROUP G; STREPTOCOCCUS PYOGENES;

GENOME, BACTERIAL; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; MOLECULAR BIOLOGY; RISK FACTORS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS;

EID: 84896725776     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000047     Document Type: Review

References (94)

1. Wilson LG. The early recognition of streptococci as causes of disease. Med Hist 1987; 31:403-414.
2. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685-694.
3. Cohen-Poradosu R, Jaffe J, Lavi D, et al. Group Gstreptococcal bacteremia in Jerusalem. Emerg Infect Dis 2004; 10:1455-1460.
4. Broyles LN, Van Beneden C, Beall B, et al. Population-based study of invasive disease due to beta-hemolytic streptococci of groups other than A and B. Clin Infect Dis 2009; 48:706-712.
5. Bramhachari PV, Kaul SY, McMillan DJ, et al. Disease burden due to Streptococcus dysgalactiae subsp. equisimilis (group G and C streptococcus) is higher than that due to Streptococcus pyogenes among Mumbai school children. J Med Microbiol 2010; 59:220-223.
6. Lancefield RC. A serological differentiation of human and other groups of hemolytic streptococci. J Exp Med 1933; 57:571-595.
7. Brandt CM, Haase G, Schnitzler N, et al. Characterization of blood culture isolates of Streptococcus dysgalactiae subsp. equisimilis possessing Lancefield's group A antigen. J Clin Microbiol 1999; 37:4194-4197.
8. Del Giudice P, van der Mee-Marquet N, David-Rubin F, et al. Severe relapsing erysipelas associated with chronic Streptococcus agalactiae vaginal colonization. Clin Infect Dis 2006; 43:e67-e70.
9. Sendi P, Graber P, Johansson L, et al. Streptococcus agalactiae in relapsing cellulitis. Clin Infect Dis 2007; 44:1141-1142.
10. Jensen A, Kilian M. Delineation of Streptococcus dysgalactiae, its subspecies, and its clinical and phylogenetic relationship to Streptococcus pyogenes. J Clin Microbiol 2012; 50:113-126.
11. McMillan DJ, Bessen DE, Pinho M, et al. Population genetics of Streptococcus dysgalactiae subspecies equisimilis reveals widely dispersed clones and extensive recombination. PLoS ONE 2010; 5:e11741.
12. Lamagni TL, Neal S, Keshishian C, et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004. Emerg Infect Dis 2008; 14:202-209.
13. Stockmann C, Ampofo K, Hersh AL, et al. Evolving epidemiologic characteristics of invasive group a streptococcal disease in Utah, 2002-2010. Clin Infect Dis 2012; 55:479-487.
14. Harris P, Siew DA, Proud M, et al. Bacteraemia caused by beta-haemolytic streptococci in North Queensland: changing trends over a 14-year period. Clin Microbiol Infect 2011; 17:1216-1222.
15. Kittang BR, Bruun T, Langeland N, et al. Invasive group A, C and G streptococcal disease in western Norway: virulence gene profiles, clinical features and outcomes. Clin Microbiol Infect 2011; 17:358-364.
16. Loubinoux J, Plainvert C, Collobert G, et al. Adult invasive and noninvasive infections due to Streptococcus dysgalactiae subsp. equisimilis in France from 2006 to 2010. J Clin Microbiol 2013; 51:2724-2727.
17. Rantala S, Vahakuopus S, Vuopio-Varkila J, et al. Streptococcus dysgalactiae subsp. equisimilis bacteremia, Finland, 1995-2004. Emerg Infect Dis 2010; 16:843-846.
18. Health Protection Agency. Pyogenic and non-pyogenic streptococcal bacteraemia, England, Wales and Northern Ireland: 2011. In: Health Protection Report HPA; Nov 2012. vol 6, number 46.
19. Luca-Harari B, Darenberg J, Neal S, et al. Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2009; 47:1155-1165.
20. Kittang BR, Skrede S, Langeland N, et al. emm gene diversity, superantigen gene profiles and presence of SlaA among clinical isolates of group A, C and G streptococci from western Norway. Eur J Clin Microbiol Infect Dis 2011; 30:423-433.
21. Vahakuopus S, Vuento R, Siljander T, et al. Distribution of emm types in invasive and noninvasive group A and G streptococci. Eur J Clin Microbiol Infect Dis 2012; 31:1251-1256.
22. Zachariadou L, Stathi A, Tassios PT, et al. Differences in the epidemiology between paediatric and adult invasive Streptococcus pyogenes infections. Epidemiol Infect 2013; 1-8.
23. Mcgrath JA, Eady RAJ, Pope FM. Aatomy and organization of human skin. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's textbook of dermatology, 7th ed. Malden, MA, USA: Blackwell Publishing Inc; 2004. pp. 45-128.
24. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334:240-245.
25. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373-1406.
26. Das DK, Baker MG, Venugopal K. Risk factors, microbiological findings and outcomes of necrotizing fasciitis in New Zealand: a retrospective chart review. BMC Infect Dis 2012; 12:348.
27. Bruun T, Kittang BR, de Hoog BJ, et al. Necrotizing soft tissue infections caused by Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis of groups C and G in western Norway. Clin Microbiol Infect 2013; 19:E545-E550.
28. Das DK, Baker MG, Venugopal K. Increasing incidence of necrotizing fasciitis in New Zealand: a nationwide study over the period 1990 to 2006. J Infect 63 2011; 429-433.
29. Hassell M, Fagan P, Carson P, Currie BJ. Streptococcal necrotising fasciitis from diverse strains of Streptococcus pyogenes in tropical northern Australia: case series and comparison with the literature. BMC Infect Dis 2004; 4:60.
30. Towers RJ, Carapetis JR, Currie BJ, et al. Extensive diversity of Streptococcus pyogenes in a remote human population reflects global-scale transmission rather than localised diversification. PLoS ONE 2013; 8:e73851.
31. Harris SR, Cartwright EJP, Török ME, et al. Whole-genome sequencing for analysis of an outbreak of meticillin-resistant Staphylococcus aureus: a descriptive study. Lancet Infect Dis 2013; 13:130-136.
32. Reuter S, Ellington MJ, Cartwright EP, et al. Rapid bacterial whole-genome sequencing to enhance diagnostic and public health microbiology. JAMA Int Med 2013; 173:1397-1404.
33. Turner CE, Dryden M, Holden MTG, et al. Molecular analysis of an outbreak of lethal postpartum sepsis caused by Streptococcus pyogenes. J Clin Microbiol 2013; 51:2089-2095.
34. Ben Zakour NL, Venturini C, Beatson SA, Walker MJ. Analysis of a Streptococcus pyogenes puerperal sepsis cluster by use of whole-genome sequencing. J Clin Microbiol 2012; 50:2224-2228.
35. Chen M, Yao W, Wang X, et al. Outbreak of scarlet fever associated with emm12 type group A Streptococcus in 2011 in Shanghai, China. Pediatr Infect Dis J 2012; 31:e158-e162.
36. Lau EH, Nishiura H, Cowling BJ, et al. Scarlet fever outbreak, Hong Kong, 2011. Emerg Infect Dis 2012; 18:1700-1702.
37. Yang P, Peng X, Zhang D, et al. Characteristics of group A Streptococcus strains circulating during scarlet fever epidemic, Beijing, China, 2011. Emerg Infect Dis 2013; 19:909-915.
38. Luk EY, Lo JY, Li AZ, et al. Scarlet fever epidemic, Hong Kong, 2011. Emerg Infect Dis 2012; 18:1658-1661.
39. Tse H, Bao JY, Davies MR, et al. Molecular characterization of the 2011 Hong Kong scarlet fever outbreak. J Infect Dis 2012; 206:341-351.
40. Becherelli M, Manetti AG, Buccato S, et al. The ancillary protein 1 of Streptococcus pyogenes FCT-1 pili mediates cell adhesion and biofilm formation through heterophilic as well as homophilic interactions. Mol Microbiol 2012; 83:1035-1047.
41. Caswell CC, Oliver-Kozup H, Han R, et al. Scl1, the multifunctional adhesin of group A Streptococcus, selectively binds cellular fibronectin and laminin, and mediates pathogen internalization by human cells. FEMS Microbiology Letters 2010; 303:61-68.
42. Kimura KR, Nakata M, Sumitomo T, et al. Involvement of T6 pili in biofilm formation by serotype M6 Streptococcus pyogenes. J Bacteriol 2012; 194:804-812.
43. Oliver-Kozup H, Martin KH, Schwegler-Berry D, et al. The group A streptococcal collagen-like protein-1, Scl1, mediates biofilm formation by targeting the extra domain A-containing variant of cellular fibronectin expressed in wounded tissue. Mol Microbiol 2013; 87:672-689.
44. Chang JC, LaSarre B, Jimenez JC, et al. Two group A streptococcal peptide pheromones act through opposing Rgg regulators to control biofilm development. PLoS Pathog 2011; 7:e1002190.
45. Lasarre B, Chang JC, Federle MJ. Redundant group A streptococcus signaling peptides exhibit unique activation potentials. J Bacteriol 2013; 195:4310-4318.
46. Lasarre B, Aggarwal C, Federle MJ. Antagonistic Rgg regulators mediate quorum sensing via competitive DNA binding in Streptococcus pyogenes. MBio 2013; 3:e00333-12.
47. Cook LC, LaSarre B, Federle MJ. Interspecies communication among commensal and pathogenic streptococci. MBio 2013; 4:e00382-13.
48. Michael-Gayego A, Dan-Goor M, Jaffe J, et al. Characterization of the sil in invasive groups A andG streptococci; antibodies against bacterial pheromone peptide SilCR result in severe infection. Infect Immun 2013; 81:4121-4127.
49. Belotserkovsky I, Baruch M, Peer A, et al. Functional analysis of the quorumsensing streptococcal invasion locus (sil). PLoS Pathog 2009; 5:e1000651.
50. Ueda S, Uchiyama S, Azzi T, et al. Oropharyngeal group A streptococcal colonization disrupts latent Epstein-Barr virus infection. J Infect Dis 2014; 209:255-264.
51. Collin M, Olsen A. Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins. Infect Immun 2001; 69:7187-7189.
52. Wexler DE, Chenoweth DE, Cleary PP. Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci U S A 1985; 82:8144-8148.
53. Akesson P, Sjoholm AG, Bjorck L. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function. J Biol Chem 1996; 271:1081-1088.
54. Walport MJ. Complement. N Engl J Med 2001; 344:1058-1066.
55. Agrahari G, Liang Z, Mayfield JA, et al. Complement-mediated opsonization of invasive group A Streptococcus pyogenes strain AP53 is regulated by the bacterial two-component cluster of virulence responder/sensor (CovRS) system. J Biol Chem 2013; 288:27494-27504.
56. Terao Y, Mori Y, Yamaguchi M, et al. Group A streptococcal cysteine protease degrades C3 (C3b) and contributes to evasion of innate immunity. J Biol Chem 2008; 283:6253-6260.
57. Tsao N, Tsai W-H, Lin Y-S, et al. Streptococcal pyrogenic exotoxin B cleaves properdin and inhibits complement-mediated opsonophagocytosis. Biochem Biophys Res Commun 2006; 339:779-784.
58. Honda-Ogawa M, Ogawa T, Terao Y, et al. Cysteine proteinase from Streptococcus pyogenes enables evasion of innate immunity via degradation of complement factors. J Biol Chem 2013; 288:15854-15864.
59. Barthel D, Schindler S, Zipfel PF. Plasminogen is a complement inhibitor. J Biol Chem 2012; 287:18831-18842.
60. von Pawel-Rammingen U, Johansson BP, Bjorck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J 2002; 21:1607-1615.
61. Nordenfelt P, Waldemarson S, Linder A, et al. Antibody orientation at bacterial surfaces is related to invasive infection. J Exp Med 2012; 209:2367-2381.
62. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci 1988; 85:1657-1661.
63. Kotarsky H, Hellwage J, Johnsson E, et al. Identification of a domain in human factor H and factor H-like protein-1 required for the interaction with streptococcal M proteins. J Immun 1998; 160:3349-3354.
64. Pérez-Caballero D, Albertí S, Vivanco F, et al. Assessment of the interaction of human complement regulatory proteins with group A Streptococcus. Identification of a high-affinity group A Streptococcus binding site in FHL-1. Eur J Immunol 2000; 30:1243-1253.
65. Makou E, Herbert AP, Barlow PN. Functional anatomy of complement factor H. Biochemistry 2013; 52:3949-3962.
66. Haapasalo K, Vuopio J, Syrjanen J, et al. Acquisition of complement factor H is important for pathogenesis of Streptococcus pyogenes infections: evidence from bacterial in vitro survival and human genetic association. J Immunol 2012; 188:426-435.
67. Gustafsson MC, Lannergard J, Nilsson OR, et al. Factor H binds to the hypervariable region of many Streptococcus pyogenes M proteins but does not promote phagocytosis resistance or acute virulence. PLoS Pathog 2013; 9:e1003323.
68. Johnson S, Tan L, van der Veen S, et al. Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog 2012; 8:e1002981.
69. Edwards AO, Ritter R 3rd, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308:421-424.
70. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in agerelated macular degeneration. Science 2005; 308:385-389.
71. Haapasalo K, Jarva H, Siljander T, et al. Complement factor H allotype 402H is associated with increased C3b opsonization and phagocytosis of Streptococcus pyogenes. Mol Microbiol 2008; 70:583-594.
72. Magnusson KP, Duan S, Sigurdsson H, et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med 2006; 3:e5.
73. Graham MR, Smoot LM, Migliaccio CAL, et al. Virulence control in group A Streptococcus by a two-component gene regulatory system: Global expression profiling and in vivo infection modeling. Proc Natl Acad Sci 2002; 99:13855-13860.
74. Joiner KA, Brown EJ, Frank MM. Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol 1984; 2:461-491.
75. Berends ET, Dekkers JF, Nijland R, et al. Distinct localization of the complement C5b-9 complex on Gram-positive bacteria. Cell Microbiol 2013; 15:1955-1968.
76. Oppegaard O, Mylvaganam H, Skrede S, et al. Sequence diversity of sicG among group C and G Streptococcus dysgalactiae subspecies equisimilis isolates associated with human infections in western Norway. Eur J Clin Microbiol Infect Dis 2013. [Epub ahead of print]
77. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359:938-949.
78. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13:34-45.
79. Loof TG, Morgelin M, Johansson L, et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 2011; 118:2589-2598.
80. Pahlman LI, Morgelin M, Kasetty G, et al. Antimicrobial activity of fibrinogen and fibrinogen-derived peptides: a novel link between coagulation and innate immunity. Thromb Haemost 2013; 109:930-939.
81. Oehmcke S, Mörgelin M, Malmström J, et al. Stimulation of blood mononuclear cells with bacterial virulence factors leads to the release of procoagulant and pro-inflammatory microparticles. Cell Microbiol 2012; 14:107-119.
82. Oehmcke S, Westman J, Malmstrom J, et al. A novel role for pro-coagulant microvesicles in the early host defense against Streptococcus pyogenes. PLoS Pathog 2013; 9:e1003529.
83. Reddy KNN, Markus G. Mechanism of activation of human plasminogen by streptokinase: presence of active center in streptokinase-plasminogen complex. J Biol Chem 1972; 247:1683-1691.
84. Cook SM, Skora A, Gillen CM, et al. Streptokinase variants from Streptococcus pyogenes isolates display altered plasminogen activation characteristics: implications for pathogenesis. Mol Microbiol 2012; 86:1052-1062.
85. Berge A, Sjöbring U. PAM, a novel plasminogen-binding protein from Streptococcus pyogenes. J Biol Chem 1993; 268:25417-25424.
86. Pancholi V, Fischetti VA. A major surface protein on group A streptococci is a glyceraldehyde-3-phosphate-dehydrogenase with multiple binding activity. J Exp Med 1992; 176:415-426.
87. Pancholi V, Fischetti VA. α-Enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. J Biol Chem 1998; 273:14503-14515.
88. Sun H, Ringdahl U, Homeister JW, et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 2004; 305:1283-1286.
89. Hollands A, Gonzalez D, Leire E, et al. A bacterial pathogen co-opts host plasmin to resist killing by cathelicidin antimicrobial peptides. J Biol Chem 2012; 287:40891-40897.
90. Sanderson-Smith ML, Zhang Y, Ly D, et al. A key role for the urokinase plasminogen activator (uPA) in invasive Group A streptococcal infection. PLoS Pathog 2013; 9:e1003469.
91. Carlsson F, Sandin C, Lindahl G. Human fibrinogen bound to Streptococcus pyogenes Mprotein inhibits complement deposition via the classical pathway. Mol Microbiol 2005; 56:28-39.
92. Macheboeuf P, Buffalo C, Fu C-y, et al. Streptococcal M1 protein constructs a pathological host fibrinogen network. Nature 2011; 472:64-68.
93. McNamara C, Zinkernagel AS, Macheboeuf P, et al. Coiled-coil irregularities and instabilities in group A Streptococcus M1 are required for virulence. Science 2008; 319:1405-1408.
94. Uchiyama S, Andreoni F, Zurcher C, et al. Coiled-coil irregularities of the M1 protein structure promote M1-fibrinogen interaction and influence group A Streptococcus host cell interactions and virulence. J Mol Med (Berl) 2013; 91:861-869.